Xingxing reaches strategic financing partnership to help develop a new generation of myocardial myoglobulin inhibitors

Guide: Star has committed to pay the advance payment and the milestone payments required for an additional $200 million in the r.d development and commercialization process!---- committed $250 million to invest in Cytokinetics, plus an additional $200 million in research and development and commercialization milestone payments as a global biopharmaceutical and medical technology life cycle investor, RTW Investments provides Cytokinetics with a comprehensive financing solution to facilitate the development of Cytokinetics CK-274, which includes direct equity investment, direct equity investment, Product sales commission monetization and back-to-back sales commission of research and development funds Xingxing Pharmaceuticals announced that it has signed a licensing agreement for the development and commercialization of CK-274 in Greater China RTW Investments ("RTW") today is pleased to announce that it has invested in a Shanghai-based biotechnology company, Xingxing Pharmaceuticals ("Star), and Cytokintics, a company dedicated to the exploration, The clinical late-stage biopharmaceutical company that developed and commercialized first-in-class muscle activators and next-in-class muscle inhibitors has entered into an exclusive license agreement for the development and commercialization of the next generation of myomyoglobulin inhibitorCK-274 in Greater Chinastar has committed to pay the advance payment and the milestone payments required for an additional $200 million in the r and d.development and commercialization processas part of the agreement, The Star will also pay Cytokinetics a double-digit sales commission for the product in the agreement areaRTW has also entered into a more in-depth strategic financing agreement and equity purchase agreement with Cytokineticsin addition to a $50 million direct equity investment in Cytokinetics at $25 per share of common stock, RTW has committed up to $90 million in research and development funds to CK-274the development of one or both indications of obstructive and non-obstructive hypertrophy of myocardial disease, with the start of each critical clinical trial by the required dateRTW will receive a low-digit CK-274 sales commission in the United States, the European Union, the United Kingdom, Switzerland and some other European countries, RTW agreed to purchase a future sales commission for mavacamten from Cytokinetics for $85 million in cash under partial closing termsthis wide-ranging transaction highlights the complexity of financial support for science, technology innovation assets and the added value benefits that RTW and its partners bring to itRTW understands the scientific challenges of developing innovative drugs and the ability to find innovative financing solutions worldwideCK-274CK-274 is a new oral small molecule myoglobulin inhibitor developed independently by Cytokinetics scientistsCK-274 is derived from a wide range of chemical optimization projectsthe project provides a detailed look at therapeutic index and pharmacokinetic properties that are expected to be translated into clinically developed next-in-class potential drugsCK-274 is designed to reduce the high constriction of hypertrophic cardiomyopathy (HCM)in the preclinical model, CK-274 reduces myocardial contraction by binding directly with myocardial myoglobin at a unique and selective structural binding site, thereby preventing myoglobin from entering a contraction stateCK-274 reduces the number of active actin-myoglobin crossbridges in each tachycardia cycle, thereby reducing myocardial contractionthis mechanism of action may have therapeutic effects on diseases characterized by excessive contraction, such as HCMin preclinical models of cardiac function, whether in normal heart function models or in mouse HCM models, CK-274 reduces cardiac contraction in predictable dose and dose-dependent mannerscharacterized, evaluated and optimized the preclinical pharmacokinetics of CK-274 to facilitate clinical dose adjustmenta Phase 1 study showed that CK-274 performed safely and well tolerated in healthy subjectsThe pharmacokinetics ofCK-274 were generally dose-linear, with significant steady state within 14 days of administrationleft ventricular blood fractions were reduced in a way that exposed dependence, and the calibrated protein binding differences were similar to those observed in human subjects in the pharmacokinetic/pharmacodynamic relationship of CK-274in general, the shallow exposure-reaction relationship observed before clinical use showed that it was applicable to humans and could make dose optimization flexible in humansoverall research and development program will assess the potential of CK-274 to improve motor ability and alleviate symptoms in patients with alzheimered ventricles caused by HCM